Capricor Therapeutics Inc (CAPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Capricor Therapeutics Inc (CAPR) has a cash flow conversion efficiency ratio of -0.077x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.57 Million) by net assets ($305.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Capricor Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Capricor Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CAPR total liabilities for a breakdown of total debt and financial obligations.
Capricor Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Capricor Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
-0.034x |
|
ONESPAWORLD HLDGS DL-0001
F:ORW
|
N/A |
|
Guangzhou Fangbang Electronics Co Ltd
SHG:688020
|
0.018x |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
-0.034x |
|
Tootsie Roll Industries Inc
NYSE:TR
|
0.068x |
|
Yelp Inc
NYSE:YELP
|
0.179x |
|
Jiangsu Cai Qin Technology Co Ltd
SHG:688182
|
-0.002x |
|
Fulltech Fiber Glass
TWO:1815
|
0.023x |
Annual Cash Flow Conversion Efficiency for Capricor Therapeutics Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Capricor Therapeutics Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see CAPR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.79 Million | $-69.81 Billion | -228.296x | -82930.18% |
| 2024-12-31 | $145.46 Million | $-40.00 Million | -0.275x | +75.72% |
| 2023-12-31 | $22.60 Million | $-25.60 Million | -1.133x | -371.49% |
| 2022-12-31 | $11.79 Million | $4.92 Million | 0.417x | +177.85% |
| 2021-12-31 | $31.37 Million | $-16.81 Million | -0.536x | -50.29% |
| 2020-12-31 | $28.20 Million | $-10.05 Million | -0.357x | +64.25% |
| 2019-12-31 | $6.84 Million | $-6.82 Million | -0.997x | +66.79% |
| 2018-12-31 | $4.62 Million | $-13.86 Million | -3.003x | -136.94% |
| 2017-12-31 | $11.23 Million | $-14.23 Million | -1.268x | -132.11% |
| 2016-12-31 | $-4.00 Million | $-15.80 Million | 3.947x | -62.35% |
| 2015-12-31 | $-1.03 Million | $-10.82 Million | 10.484x | +6934.47% |
| 2014-12-31 | $-6.25 Million | $958.56K | -0.153x | -101.34% |
| 2013-12-31 | $-534.88K | $-6.14 Million | 11.487x | +2671.04% |
| 2012-12-31 | $4.89 Million | $-2.19 Million | -0.447x | +92.02% |
| 2011-12-31 | $830.72K | $-4.65 Million | -5.597x | -236.57% |
| 2010-12-31 | $2.60 Million | $-4.32 Million | -1.663x | +14.43% |
| 2009-12-31 | $2.98 Million | $-5.80 Million | -1.943x | +6.78% |
| 2008-12-31 | $5.10 Million | $-10.64 Million | -2.085x | -489.82% |
| 2007-12-31 | $15.20 Million | $-5.37 Million | -0.353x | -183.02% |
| 2006-12-31 | $-130.58K | $-55.60K | 0.426x | +85.78% |
| 2005-12-31 | $-77.62K | $-17.79K | 0.229x | -13.00% |
| 2004-12-31 | $-58.76K | $-15.48K | 0.263x | -48.52% |
| 2003-12-31 | $-40.69K | $-20.82K | 0.512x | -12.35% |
| 2002-12-31 | $-24.53K | $-14.32K | 0.584x | -59.91% |
| 2001-12-31 | $-8.94K | $-13.02K | 1.456x | +152.13% |
| 2000-12-31 | $13.36K | $-37.32K | -2.793x | -291.50% |
| 1999-12-31 | $-617.00 | $-900.00 | 1.459x | -- |
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treat… Read more